• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

ONECUT2 is a novel target for treatment of castration-resistant prostate cancer.

作者信息

Joglekar Tejashree, Lin Jianqing, Shibata Maho

机构信息

Department of Anatomy and Cell Biology, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA.

The George Washington University Cancer Center, The George Washington University School of Medicine and Health Sciences, Washington, DC, USA.

出版信息

Expert Opin Ther Targets. 2020 Feb;24(2):89-90. doi: 10.1080/14728222.2020.1723080. Epub 2020 Feb 3.

DOI:10.1080/14728222.2020.1723080
PMID:31983247
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7523780/
Abstract
摘要

相似文献

1
ONECUT2 is a novel target for treatment of castration-resistant prostate cancer.ONECUT2是去势抵抗性前列腺癌治疗的新靶点。
Expert Opin Ther Targets. 2020 Feb;24(2):89-90. doi: 10.1080/14728222.2020.1723080. Epub 2020 Feb 3.
2
Targeting the androgen receptor in metastatic castration-resistant prostate cancer.靶向转移性去势抵抗性前列腺癌中的雄激素受体
Future Oncol. 2014 Feb;10(3):329-32. doi: 10.2217/fon.13.255.
3
ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis.ONECUT2 是一种可靶向的致命前列腺癌主调控因子，可抑制雄激素轴。
Nat Med. 2018 Dec;24(12):1887-1898. doi: 10.1038/s41591-018-0241-1. Epub 2018 Nov 26.
4
Leading causes of castration-resistant prostate cancer.去势抵抗性前列腺癌的主要病因。
Expert Rev Anticancer Ther. 2015 Apr;15(4):425-32. doi: 10.1586/14737140.2015.1007957. Epub 2015 Feb 3.
5
Targeting Bromodomain and Extra-Terminal (BET) Family Proteins in Castration-Resistant Prostate Cancer (CRPC).针对去势抵抗性前列腺癌（CRPC）中的溴结构域和末端（BET）家族蛋白。
Clin Cancer Res. 2018 Jul 1;24(13):3149-3162. doi: 10.1158/1078-0432.CCR-17-3571. Epub 2018 Mar 19.
6
Interference with the androgen receptor protein stability in therapy-resistant prostate cancer.治疗抵抗性前列腺癌中雄激素受体蛋白稳定性的干扰。
Int J Cancer. 2019 Apr 15;144(8):1775-1779. doi: 10.1002/ijc.31818. Epub 2018 Nov 4.
7
BAG1L: a promising therapeutic target for androgen receptor-dependent prostate cancer.BAG1L：雄激素受体依赖性前列腺癌有前途的治疗靶点。
J Mol Endocrinol. 2019 May;62(4):R289-R299. doi: 10.1530/JME-19-0034.
8
Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer.靶向去势抵抗性前列腺癌中的雄激素受体异常
Clin Cancer Res. 2016 Sep 1;22(17):4280-2. doi: 10.1158/1078-0432.CCR-16-1137. Epub 2016 Jun 21.
9
20(S)-protopanaxadiol inhibition of progression and growth of castration-resistant prostate cancer.20(S)-原人参二醇对去势抵抗性前列腺癌进展和生长的抑制作用
PLoS One. 2014 Nov 6;9(11):e111201. doi: 10.1371/journal.pone.0111201. eCollection 2014.
10
CH5137291, an androgen receptor nuclear translocation-inhibiting compound, inhibits the growth of castration-resistant prostate cancer cells.CH5137291是一种雄激素受体核易位抑制化合物，可抑制去势抵抗性前列腺癌细胞的生长。
Int J Oncol. 2015 Apr;46(4):1560-72. doi: 10.3892/ijo.2015.2860. Epub 2015 Jan 30.

引用本文的文献

1
ONECUT2 reprograms neuroendocrine fate and is an actionable therapeutic target in small cell lung cancer.ONECUT2重编程神经内分泌命运，是小细胞肺癌中一个可用于治疗的靶点。
Mol Med. 2025 Jun 11;31(1):232. doi: 10.1186/s10020-025-01267-6.
2
Prostate luminal cell plasticity and cancer.前列腺管腔细胞可塑性与癌症
Cancer Lett. 2024 Dec 25;611:217430. doi: 10.1016/j.canlet.2024.217430.
3
Integrative analysis identifies the atypical repressor E2F8 as a targetable transcriptional activator driving lethal prostate cancer.整合分析确定非典型阻遏物E2F8是驱动致死性前列腺癌的可靶向转录激活因子。
Oncogene. 2025 Mar;44(8):481-493. doi: 10.1038/s41388-024-03239-2. Epub 2024 Nov 29.
4
Identification of EMT-Related Gene Signatures to Predict the Prognosis of Patients With Endometrial Cancer.鉴定与上皮-间质转化相关的基因特征以预测子宫内膜癌患者的预后
Front Genet. 2020 Dec 2;11:582274. doi: 10.3389/fgene.2020.582274. eCollection 2020.

本文引用的文献

1
ONECUT2 overexpression promotes RAS-driven lung adenocarcinoma progression.ONECUT2 过表达促进 RAS 驱动的肺腺癌进展。
Sci Rep. 2019 Dec 27;9(1):20021. doi: 10.1038/s41598-019-56277-2.
2
ONECUT2 is a driver of neuroendocrine prostate cancer.ONECUT2 是神经内分泌前列腺癌的驱动基因。
Nat Commun. 2019 Jan 17;10(1):278. doi: 10.1038/s41467-018-08133-6.
3
ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis.ONECUT2 是一种可靶向的致命前列腺癌主调控因子，可抑制雄激素轴。
Nat Med. 2018 Dec;24(12):1887-1898. doi: 10.1038/s41591-018-0241-1. Epub 2018 Nov 26.
4
Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses.将前列腺癌细胞 AR 异质性与不同的去势和恩杂鲁胺反应联系起来。
Nat Commun. 2018 Sep 6;9(1):3600. doi: 10.1038/s41467-018-06067-7.
5
Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling.雄激素受体信号通路非依赖性前列腺癌通过成纤维细胞生长因子信号得以维持。
Cancer Cell. 2017 Oct 9;32(4):474-489.e6. doi: 10.1016/j.ccell.2017.09.003.
6
Transdifferentiation as a Mechanism of Treatment Resistance in a Mouse Model of Castration-Resistant Prostate Cancer.去势抵抗性前列腺癌小鼠模型中作为治疗抵抗机制的转分化
Cancer Discov. 2017 Jul;7(7):736-749. doi: 10.1158/2159-8290.CD-16-1174. Epub 2017 Apr 14.
7
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer.去势抵抗性神经内分泌前列腺癌的不同克隆进化
Nat Med. 2016 Mar;22(3):298-305. doi: 10.1038/nm.4045. Epub 2016 Feb 8.
8
The Placental Gene PEG10 Promotes Progression of Neuroendocrine Prostate Cancer.胎盘基因PEG10促进神经内分泌前列腺癌进展。
Cell Rep. 2015 Aug 11;12(6):922-36. doi: 10.1016/j.celrep.2015.07.012. Epub 2015 Jul 30.
9
Platinum-based chemotherapy for variant castrate-resistant prostate cancer.铂类化疗治疗变异型去势抵抗性前列腺癌。
Clin Cancer Res. 2013 Jul 1;19(13):3621-30. doi: 10.1158/1078-0432.CCR-12-3791. Epub 2013 May 6.
10
From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer.从序列到分子病理学，以及驱动前列腺癌神经内分泌表型的机制。
J Pathol. 2012 Jul;227(3):286-97. doi: 10.1002/path.4047.